Do analysts rate JLHL or DFIN?

Donnelley Financial Solutions has a consensus price target of $59.50, suggesting a potential upside of 54.19%. Given Donnelley Financial Solutions' stronger consensus rating and higher possible upside, analysts plainly believe Donnelley Financial Solutions is more favorable than Julong. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Julong 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Donnelley Financial Solutions 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.80

Which has stronger valuation and earnings, JLHL or DFIN?

Donnelley Financial Solutions has higher revenue and earnings than Julong. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Julong $35.40M 11.14 $3.67M N/A N/A Donnelley Financial Solutions $767M 1.26 $32.40M $1.29 29.91

Does the media favor JLHL or DFIN?

In the previous week, Julong had 7 more articles in the media than Donnelley Financial Solutions. MarketBeat recorded 8 mentions for Julong and 1 mentions for Donnelley Financial Solutions. Donnelley Financial Solutions' average media sentiment score of 0.68 beat Julong's score of 0.64 indicating that Donnelley Financial Solutions is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Julong 0 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Donnelley Financial Solutions 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate EEX or JLHL?

Emerald presently has a consensus price target of $5.03, indicating a potential upside of 1.11%. Given Emerald's stronger consensus rating and higher probable upside, research analysts clearly believe Emerald is more favorable than Julong. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Emerald 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Julong 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, EEX or JLHL?

Julong has lower revenue, but higher earnings than Emerald. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Emerald $463.40M 2.12 -$30.70M -$0.19 N/A Julong $35.40M 11.14 $3.67M N/A N/A

Is EEX or JLHL more profitable?

Julong has a net margin of 0.00% compared to Emerald's net margin of -8.24%. Julong's return on equity of 0.00% beat Emerald's return on equity. Company Net Margins Return on Equity Return on Assets Emerald -8.24% -10.81% -3.18% Julong N/A N/A N/A

Does the media prefer EEX or JLHL?

In the previous week, Julong had 7 more articles in the media than Emerald. MarketBeat recorded 8 mentions for Julong and 1 mentions for Emerald. Julong's average media sentiment score of 0.64 beat Emerald's score of -0.50 indicating that Julong is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Emerald 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Julong 0 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend GDRX or JLHL?

GoodRx presently has a consensus price target of $3.81, suggesting a potential upside of 35.68%. Given GoodRx's stronger consensus rating and higher probable upside, analysts plainly believe GoodRx is more favorable than Julong. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GoodRx 3 Sell rating(s) 7 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.13 Julong 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, GDRX or JLHL?

GoodRx has higher revenue and earnings than Julong. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GoodRx $796.85M 1.21 $30.44M $0.06 46.83 Julong $35.40M 11.14 $3.67M N/A N/A

Is GDRX or JLHL more profitable?

GoodRx has a net margin of 2.61% compared to Julong's net margin of 0.00%. GoodRx's return on equity of 7.90% beat Julong's return on equity. Company Net Margins Return on Equity Return on Assets GoodRx 2.61% 7.90% 3.23% Julong N/A N/A N/A

Does the media favor GDRX or JLHL?

In the previous week, Julong had 6 more articles in the media than GoodRx. MarketBeat recorded 8 mentions for Julong and 2 mentions for GoodRx. Julong's average media sentiment score of 0.64 beat GoodRx's score of 0.63 indicating that Julong is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GoodRx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Julong 0 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate CRTO or JLHL?

Criteo currently has a consensus price target of $27.94, suggesting a potential upside of 62.94%. Given Criteo's stronger consensus rating and higher probable upside, equities analysts clearly believe Criteo is more favorable than Julong. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Criteo 1 Sell rating(s) 3 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.44 Julong 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, CRTO or JLHL?

Criteo has higher revenue and earnings than Julong. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Criteo $1.94B 0.44 $144.60M $2.14 8.01 Julong $35.40M 11.14 $3.67M N/A N/A

Is CRTO or JLHL more profitable?

Criteo has a net margin of 6.06% compared to Julong's net margin of 0.00%. Criteo's return on equity of 14.98% beat Julong's return on equity. Company Net Margins Return on Equity Return on Assets Criteo 6.06% 14.98% 8.25% Julong N/A N/A N/A

Does the media prefer CRTO or JLHL?

In the previous week, Julong had 2 more articles in the media than Criteo. MarketBeat recorded 8 mentions for Julong and 6 mentions for Criteo. Criteo's average media sentiment score of 0.87 beat Julong's score of 0.64 indicating that Criteo is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Criteo 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Julong 0 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend JLHL or AHG?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Julong 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Akso Health Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, JLHL or AHG?

Julong has higher revenue and earnings than Akso Health Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Julong $35.40M 11.14 $3.67M N/A N/A Akso Health Group $14.78M 57.50 -$134.98M N/A N/A

Is JLHL or AHG more profitable?

Company Net Margins Return on Equity Return on Assets Julong N/A N/A N/A Akso Health Group N/A N/A N/A

Trading of Julong was halted at 11:25 AM EST due to "LULD Pause".

Julong (JLHL) Competitors

$34.44 +12.06 (+53.89%)

Closing price 04:00 PM Eastern

Extended Trading

$32.71 -1.73 (-5.02%)

As of 07:59 PM Eastern

Compare

JLHL vs. DFIN, EEX, GDRX, CRTO, and AHG

Should you buy Julong stock or one of its competitors? MarketBeat compares Julong with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Julong include Donnelley Financial Solutions (DFIN), Emerald (EEX), GoodRx (GDRX), Criteo (CRTO), and Akso Health Group (AHG). These companies are all part of the "business services" industry.

How does Julong compare to Donnelley Financial Solutions?

Julong (NASDAQ:JLHL) and Donnelley Financial Solutions (NYSE:DFIN) are both small-cap business services companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation and profitability.

Donnelley Financial Solutions has a consensus price target of $59.50, suggesting a potential upside of 54.19%. Given Donnelley Financial Solutions' stronger consensus rating and higher possible upside, analysts plainly believe Donnelley Financial Solutions is more favorable than Julong.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Julong	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Donnelley Financial Solutions	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.80

Donnelley Financial Solutions has higher revenue and earnings than Julong.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Julong	$35.40M	11.14	$3.67M	N/A	N/A
Donnelley Financial Solutions	$767M	1.26	$32.40M	$1.29	29.91

Donnelley Financial Solutions has a net margin of 4.52% compared to Julong's net margin of 0.00%. Donnelley Financial Solutions' return on equity of 24.80% beat Julong's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Julong	N/A	N/A	N/A
Donnelley Financial Solutions	4.52%	24.80%	11.99%

93.8% of Donnelley Financial Solutions shares are held by institutional investors. 5.2% of Donnelley Financial Solutions shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Julong had 7 more articles in the media than Donnelley Financial Solutions. MarketBeat recorded 8 mentions for Julong and 1 mentions for Donnelley Financial Solutions. Donnelley Financial Solutions' average media sentiment score of 0.68 beat Julong's score of 0.64 indicating that Donnelley Financial Solutions is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Julong	0 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Donnelley Financial Solutions	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Donnelley Financial Solutions beats Julong on 12 of the 14 factors compared between the two stocks.

How does Julong compare to Emerald?

Emerald (NYSE:EEX) and Julong (NASDAQ:JLHL) are both small-cap business services companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk.

Julong has a net margin of 0.00% compared to Emerald's net margin of -8.24%. Julong's return on equity of 0.00% beat Emerald's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Emerald	-8.24%	-10.81%	-3.18%
Julong	N/A	N/A	N/A

Julong has lower revenue, but higher earnings than Emerald.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Emerald	$463.40M	2.12	-$30.70M	-$0.19	N/A
Julong	$35.40M	11.14	$3.67M	N/A	N/A

In the previous week, Julong had 7 more articles in the media than Emerald. MarketBeat recorded 8 mentions for Julong and 1 mentions for Emerald. Julong's average media sentiment score of 0.64 beat Emerald's score of -0.50 indicating that Julong is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Emerald	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Julong	0 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

14.9% of Emerald shares are held by institutional investors. 5.3% of Emerald shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Emerald presently has a consensus price target of $5.03, indicating a potential upside of 1.11%. Given Emerald's stronger consensus rating and higher probable upside, research analysts clearly believe Emerald is more favorable than Julong.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Emerald	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Julong	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Julong beats Emerald on 7 of the 12 factors compared between the two stocks.

How does Julong compare to GoodRx?

GoodRx (NASDAQ:GDRX) and Julong (NASDAQ:JLHL) are both small-cap business services companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, media sentiment, risk, analyst recommendations, earnings and institutional ownership.

GoodRx presently has a consensus price target of $3.81, suggesting a potential upside of 35.68%. Given GoodRx's stronger consensus rating and higher probable upside, analysts plainly believe GoodRx is more favorable than Julong.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GoodRx	3 Sell rating(s)	7 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.13
Julong	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

GoodRx has higher revenue and earnings than Julong.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GoodRx	$796.85M	1.21	$30.44M	$0.06	46.83
Julong	$35.40M	11.14	$3.67M	N/A	N/A

In the previous week, Julong had 6 more articles in the media than GoodRx. MarketBeat recorded 8 mentions for Julong and 2 mentions for GoodRx. Julong's average media sentiment score of 0.64 beat GoodRx's score of 0.63 indicating that Julong is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GoodRx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Julong	0 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

63.8% of GoodRx shares are held by institutional investors. 5.9% of GoodRx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

GoodRx has a net margin of 2.61% compared to Julong's net margin of 0.00%. GoodRx's return on equity of 7.90% beat Julong's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GoodRx	2.61%	7.90%	3.23%
Julong	N/A	N/A	N/A

Summary

GoodRx beats Julong on 10 of the 13 factors compared between the two stocks.

How does Julong compare to Criteo?

Criteo (NASDAQ:CRTO) and Julong (NASDAQ:JLHL) are both small-cap business services companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.

94.3% of Criteo shares are held by institutional investors. 1.5% of Criteo shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Criteo has a net margin of 6.06% compared to Julong's net margin of 0.00%. Criteo's return on equity of 14.98% beat Julong's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Criteo	6.06%	14.98%	8.25%
Julong	N/A	N/A	N/A

Criteo has higher revenue and earnings than Julong.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Criteo	$1.94B	0.44	$144.60M	$2.14	8.01
Julong	$35.40M	11.14	$3.67M	N/A	N/A

In the previous week, Julong had 2 more articles in the media than Criteo. MarketBeat recorded 8 mentions for Julong and 6 mentions for Criteo. Criteo's average media sentiment score of 0.87 beat Julong's score of 0.64 indicating that Criteo is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Criteo	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Julong	0 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Criteo currently has a consensus price target of $27.94, suggesting a potential upside of 62.94%. Given Criteo's stronger consensus rating and higher probable upside, equities analysts clearly believe Criteo is more favorable than Julong.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Criteo	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
Julong	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Criteo beats Julong on 11 of the 13 factors compared between the two stocks.

How does Julong compare to Akso Health Group?

Julong (NASDAQ:JLHL) and Akso Health Group (NASDAQ:AHG) are both small-cap business services companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment.

1.2% of Akso Health Group shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Julong	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Akso Health Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Julong had 7 more articles in the media than Akso Health Group. MarketBeat recorded 8 mentions for Julong and 1 mentions for Akso Health Group. Akso Health Group's average media sentiment score of 1.87 beat Julong's score of 0.64 indicating that Akso Health Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Julong	Positive
Akso Health Group	Very Positive

Company	Net Margins	Return on Equity	Return on Assets
Julong	N/A	N/A	N/A
Akso Health Group	N/A	N/A	N/A

Julong has higher revenue and earnings than Akso Health Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Julong	$35.40M	11.14	$3.67M	N/A	N/A
Akso Health Group	$14.78M	57.50	-$134.98M	N/A	N/A

Summary

Julong and Akso Health Group tied by winning 3 of the 6 factors compared between the two stocks.

Get Julong News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JLHL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

JLHL vs. The Competition

Export

Metric	Julong	Services – Engineering, Accounting, Surveying Industry	Services Sector	NASDAQ Exchange
Market Cap	$256.22M	$218.03M	$1.00B	$12.42B
Dividend Yield	N/A	N/A	4.81%	5.29%
P/E Ratio	N/A	10.79	9.10	24.19
Price / Sales	11.14	7.39	62.87	138.36
Price / Cash	N/A	19.85	327.75	57.88
Price / Book	N/A	5.01	6.66	6.72
Net Income	$3.67M	$3.09M	-$13.24M	$337.19M
7 Day Performance	53.48%	25.94%	2.26%	0.48%
1 Month Performance	200.79%	93.25%	40.86%	5.07%
1 Year Performance	N/A	N/A	48.46%	34.25%

Julong Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
JLHL Julong	N/A	$34.44 +53.9%	N/A	N/A	$256.22M	$35.40M	N/A	42	News Coverage Trading Halted High Trading Volume
DFIN Donnelley Financial Solutions	4.57 of 5 stars	$39.51 +0.9%	$59.50 +50.6%	-25.7%	$986.91M	$767M	30.63	1,750
EEX Emerald	0.8127 of 5 stars	$4.98 -0.1%	$5.03 +1.1%	+7.7%	$985.00M	$463.40M	N/A	600	Analyst Upgrade High Trading Volume
GDRX GoodRx	3.5078 of 5 stars	$2.56 +1.6%	$3.81 +48.9%	-22.8%	$876.99M	$787.89M	42.67	950
CRTO Criteo	4.9601 of 5 stars	$17.17 -0.4%	$27.94 +62.8%	-26.0%	$856.10M	$1.94B	8.02	3,649

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:JLHL) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Julong (JLHL) Competitors

JLHL vs. DFIN, EEX, GDRX, CRTO, and AHG

How does Julong compare to Donnelley Financial Solutions?

Summary

How does Julong compare to Emerald?

Summary

How does Julong compare to GoodRx?

Summary

How does Julong compare to Criteo?

Summary

How does Julong compare to Akso Health Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JLHL vs. The Competition

Julong Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Julong (JLHL) Competitors

JLHL vs. DFIN, EEX, GDRX, CRTO, and AHG

How does Julong compare to Donnelley Financial Solutions?

Do analysts rate JLHL or DFIN?

Which has stronger valuation and earnings, JLHL or DFIN?

Is JLHL or DFIN more profitable?

Do institutionals & insiders believe in JLHL or DFIN?

Does the media favor JLHL or DFIN?

Summary

How does Julong compare to Emerald?

Is EEX or JLHL more profitable?

Which has better valuation and earnings, EEX or JLHL?

Does the media prefer EEX or JLHL?

Do institutionals and insiders have more ownership in EEX or JLHL?

Do analysts rate EEX or JLHL?

Summary

How does Julong compare to GoodRx?

Do analysts recommend GDRX or JLHL?

Which has higher valuation and earnings, GDRX or JLHL?

Does the media favor GDRX or JLHL?

Do institutionals & insiders hold more shares of GDRX or JLHL?

Is GDRX or JLHL more profitable?

Summary

How does Julong compare to Criteo?

Do institutionals & insiders believe in CRTO or JLHL?

Is CRTO or JLHL more profitable?

Which has higher earnings and valuation, CRTO or JLHL?

Does the media prefer CRTO or JLHL?

Do analysts rate CRTO or JLHL?

Summary

How does Julong compare to Akso Health Group?

Do institutionals & insiders believe in JLHL or AHG?

Do analysts recommend JLHL or AHG?

Does the media prefer JLHL or AHG?

Is JLHL or AHG more profitable?

Which has higher valuation and earnings, JLHL or AHG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JLHL vs. The Competition

Julong Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools